2024
Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification
Ghosh A, Venkatraman S, Nanna M, Safford M, Colantonio L, Brown T, Pinheiro L, Peterson E, Navar A, Sterling M, Soroka O, Nahid M, Banerjee S, Goyal P. Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification. JAMA Cardiology 2024, 9: 55-62. PMID: 38055247, PMCID: PMC10701663, DOI: 10.1001/jamacardio.2023.4520.Peer-Reviewed Original ResearchConceptsLipoprotein cholesterol levelsAtherosclerotic cardiovascular diseaseCohort studyREGARDS cohortCholesterol levelsCardiovascular diseaseLow-density lipoprotein cholesterol levelsCoronary heart disease deathDensity lipoprotein cholesterol levelsRace-sex stratumHeart disease deathProspective cohort studyCohort risk equationsRisk predictionRace stratificationIncident ASCVDNonfatal strokeDisease deathsC-statisticMyocardial infarctionHigh riskRisk equationsSocial determinantsPercentage declineIncremental value
2023
Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice
Nanna M, Kolkailah A, Page C, Peterson E, Navar A. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice. JAMA Cardiology 2023, 8: 89-95. PMID: 36322056, PMCID: PMC9631221, DOI: 10.1001/jamacardio.2022.3839.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseUse of SGLT2iPeptide-1 receptor agonistsCotransporter 2 inhibitorsHealth care systemKidney diseaseReceptor agonistCardiovascular diseaseGlucagonlike Peptide-1 Receptor AgonistsStage 5 chronic kidney diseaseEnd-stage kidney diseaseOutpatient health care utilizationDipeptidyl peptidase-4 inhibitorsCare systemQuarter of personsSecondary prevention medicationsGlucose-lowering medicationsRetrospective cohort studyChronic kidney diseasePeptidase-4 inhibitorsElectronic health record dataHealth care utilizationRecent national guidelines
2022
Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease
Nanna M, Nelson A, Haynes K, Shambhu S, Eapen Z, Cziraky M, Calvert S, Pagidipati N, Granger C. Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease. Journal Of The American Geriatrics Society 2022, 71: 1243-1249. PMID: 36538393, PMCID: PMC10089944, DOI: 10.1111/jgs.18172.Peer-Reviewed Original ResearchConceptsHigh-intensity statinsLipid-lowering therapyModerate-intensity statinsU.S. older adultsOlder adultsPCSK9 inhibitorsNon-statin lipid-lowering therapyMulticenter retrospective cohort studyRetrospective cohort studyMinority of patientsAtherosclerotic cardiovascular diseaseCoronary artery diseaseEligible older adultsCohort studyOlder patientsOverall cohortArtery diseaseIntensive treatmentCardiovascular diseaseASCVDSecondary measuresStatinsUntreated individualsPatientsTherapyHigh-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, Calvert SB, Gallagher K, Pagidipati NJ, Granger CB. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. Journal Of The American College Of Cardiology 2022, 79: 1802-1813. PMID: 35512860, PMCID: PMC9344279, DOI: 10.1016/j.jacc.2022.02.048.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseHigh-intensity statinsStatin useYounger patientsFemale patientsHigh-intensity statin useHigher Charlson comorbidity scoreAppropriate statin useNew guideline recommendationsCharlson comorbidity scoreRetrospective cohort studyPeripheral artery diseaseModerate-intensity statinsMultivariable logistic regressionCommercial health plansMedical claims dataComorbidity scoreIndex dateCohort studyOlder patientsPreventive therapyStatin usersArtery diseaseContemporary cohortGuideline recommendations
2020
Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?
Nanna MG, Navar AM, Wojdyla D, Nelson AJ, Sullivan AE, Peterson ED. Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events? The American Journal Of Cardiology 2020, 142: 83-90. PMID: 33279483, PMCID: PMC8221431, DOI: 10.1016/j.amjcard.2020.11.027.Peer-Reviewed Original ResearchConceptsSystolic blood pressureAtherosclerotic cardiovascular diseaseAbsence of hypertensionBlood pressureCardiovascular diseaseCardiovascular eventsEvent ratesOlder adultsLower CVD event ratesLower systolic blood pressureASCVD event ratesCVD event ratesDiastolic blood pressureFuture cardiovascular eventsASCVD riskRisk stratificationPooled cohortMultivariable modelingHypertensionRisk scoreLower riskRisk estimatesNational InstituteObserved event ratesAdultsPrevalence, treatment, and control of severe hyperlipidemia
Gold ME, Nanna MG, Doerfler SM, Schibler T, Wojdyla D, Peterson ED, Navar AM. Prevalence, treatment, and control of severe hyperlipidemia. American Journal Of Preventive Cardiology 2020, 3: 100079. PMID: 34327462, PMCID: PMC8315339, DOI: 10.1016/j.ajpc.2020.100079.Peer-Reviewed Original ResearchLDL-C controlHigh-intensity statinsLDL-C levelsLow-density lipoprotein cholesterol controlLDL-C treatment goalsPrior atherosclerotic cardiovascular diseaseMultivariable logistic regression modelingHealth systemDuke University Health SystemAtherosclerotic cardiovascular diseaseLDL-C measurementAfrican American raceCross-sectional prevalenceUniversity Health SystemUnited States adultsGreater reductionLogistic regression modelingContemporary clinical practiceIntensity statinsHigh LDLAppropriate therapyCholesterol controlSevere hyperlipidemiaFemale sexCardiovascular disease
2019
The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults
Nanna MG, Peterson ED, Wojdyla D, Navar AM. The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. Journal Of General Internal Medicine 2019, 35: 1701-1708. PMID: 31667745, PMCID: PMC7280419, DOI: 10.1007/s11606-019-05361-4.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseOlder adultsACC/AHA guidelinesAge groupsLarge prospective cohort studyRisk estimatesYoung adultsASCVD risk estimationProspective cohort studyCardiovascular Health StudyHigh-risk groupU.S. older adultsDifferent age groupsCHD deathFramingham OriginalASCVD riskCardiovascular eventsAHA guidelinesCohort studyPrimary preventionCardiovascular diseaseRisk groupsTreatment decisionsFramingham OffspringHealth StudySex Differences in the Use of Statins in Community Practice
Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, Li Z, Peterson ED, Navar AM. Sex Differences in the Use of Statins in Community Practice. Circulation Cardiovascular Quality And Outcomes 2019, 12: e005562. PMID: 31416347, PMCID: PMC6903404, DOI: 10.1161/circoutcomes.118.005562.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesCommunity Health ServicesDyslipidemiasFemaleGuideline AdherenceHealth Knowledge, Attitudes, PracticeHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMedication AdherenceMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Primary PreventionRegistriesRisk AssessmentRisk FactorsSecondary PreventionSex FactorsTime FactorsTreatment OutcomeTreatment RefusalUnited StatesConceptsStatin therapyStatin treatmentStatin useCardiology/American Heart Association cholesterol guidelinesAmerican Heart Association cholesterol guidelinesGuideline-recommended statin intensityHeart Association cholesterol guidelinesSex differencesAggressive lipid managementGuideline-recommended intensityLipid Management (PALM) registrySecondary prevention indicationUse of statinsAtherosclerotic cardiovascular diseaseMultivariable logistic regressionCholesterol guidelinesStatin dosingStatin intensityLipid managementClinical characteristicsNationwide registryPrevention indicationMale patientsManagement RegistryFemale patientsThe Association Between Low‐Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts
Nanna MG, Navar AM, Wojdyla D, Peterson ED. The Association Between Low‐Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. Journal Of The American Geriatrics Society 2019, 67: 2560-2567. PMID: 31411740, PMCID: PMC6898756, DOI: 10.1111/jgs.16123.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseLow-density lipoprotein cholesterolIncident atherosclerotic cardiovascular diseaseRisk factorsEvent ratesLipoprotein cholesterolPooled cohortCardiovascular diseaseMultivariable-adjusted Cox proportional hazards modelsElevated low-density lipoprotein cholesterolIndividual level cohort dataCox proportional hazards modelOlder adultsASCVD event ratesCVD risk factorsCVD event ratesProspective cohort studyPresence of hyperlipidemiaProportional hazards modelNational InstituteCohort studyCVD riskMedian ageMedian LDLUnadjusted analysesPractice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry
Nanna MG, Navar AM, Wang TY, Li S, Virani SS, Li Z, Robinson JG, Roger VL, Wilson PWF, Goldberg AC, Koren A, Louie MJ, Peterson ED. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal 2019, 214: 113-124. PMID: 31202098, PMCID: PMC6639125, DOI: 10.1016/j.ahj.2019.05.009.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterol controlMedian odds ratioAtherosclerotic cardiovascular diseaseStatin useStatin intensityStatin therapyCholesterol controlProvider assessmentGuideline-recommended statin intensityGuideline-recommended intensityLipid Management (PALM) registrySecondary prevention patientsLDL-C levelsPractice-level variationEligible patientsStatin recommendationsStatin treatmentManagement RegistryGuideline recommendationsPatient's likelihoodUS patientsSimilar patientsTreatment indicationsUS clinicsOdds ratio